Skip to content

Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19

Exercise Therapy in Cancer Patients Hospitalized for COVID-19: A Digitized Clinical Trial

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04824443
Enrollment
3
Registered
2021-04-01
Start date
2021-03-29
Completion date
2025-10-24
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Coronavirus, Covid19

Keywords

Covid19, Coronavirus, Cancer, Exercise, 21-101, Memorial Sloan Kettering Cancer Center

Brief summary

The purpose of the study is to evaluate the safety and tolerability of a 30-week aerobic exercise therapy program in cancer patients recovering from COVID-19. The study will look at whether the aerobic exercise therapy causes few or mild side effects in participants. Aerobic exercise is physical activity that uses the large muscle groups (muscles in your legs, buttocks, back, and chest) and can be performed for several minutes at a time. The aerobic exercise therapy being used in this study will be a walking program that will be adjusted so it matches participant fitness levels (how much exercise you can handle).

Interventions

Aerobic Exercise Therapy/AT will consist of 30 weeks of treadmill walking sessions. AT will consist of supervised, individualized walking delivered up to 6 times weekly (over a 7-day period) to achieve a cumulative total duration ranging from 90 mins/wk up to 375 mins/wk following a non-linear dosing schedule. The planned dose and scheduling of AT will be continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period (i.e., non-linear periodized schedule).

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 * Previously admitted to a hospital for Covid-19 * Discharged from hospital for at least 30 days * Previously treated for cancer at MSK * Interval of ≥ 12 months but ≤ 10 years following completion of primary non-hormonal anti-cancer therapy (current endocrine therapy and maintenance therapy allowed) * Space to house a treadmill at personal residence * Cleared for exercise participation as per screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) * Performing less than 90 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self-report * If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study. * Women \<50 years old who are of child-bearing potential must have a negative pregnancy test within 14 days of enrollment.

Exclusion criteria

* Currently receiving home oxygen after discharge * Enrollment onto any other interventional investigational study * Current treatment for any other diagnosis of invasive cancer of any kind * Distant metastatic malignancy of any kind * Receiving non-hormonal anticancer therapy * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Design outcomes

Primary

MeasureTime frameDescription
Frequency of serious adverse events during study-related assessments30 weeksSafety will be evaluated by the frequency of serious (i.e., life-threatening, hospitalization, significant incapacity, important medical events) adverse events during study-related assessments and exercise sessions according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026